Will New Wave Of Antibiotics Fight Resistance?
Results from the first seven months of the Sentry AntimicrobialSurveillance study have highlighted alarming upward trends in antibiotic resistance, according to data presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Researchers from the University of Iowa College of Medicine and the Eijkman-Winkler Institute for Microbiology Infection and Inflammation at University Hospital in the Netherlands, sponsored by a grant from Bristol-Myers Squibb, designed the study which involved 68 medical centers in the USA, Canada, South America and Europe.
Almost 70 antibiotics were tested, including newer drugs such as Bayer's ciprofloxacin, Merck & Co's imipenem and Kyorin Pharmaceutical's gatifloxacin. So far 25,000 strains have been screened. Data showed:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze